Ask about this productRelated genes to: TL1A protein
- Gene:
- TNFSF15 NIH gene
- Name:
- TNF superfamily member 15
- Previous symbol:
- -
- Synonyms:
- TL1, VEGI, TL1A, VEGI192A, MGC129934, MGC129935
- Chromosome:
- 9q32
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-04
- Date modifiied:
- 2017-03-02
Related products to: TL1A protein
Related articles to: TL1A protein
- Tumor necrosis factor-like ligand 1A (TL1A), encoded by TNFSF15, signals through death receptor 3 on effector T cells, innate lymphoid cells, and intestinal myofibroblasts, driving both chronic intestinal inflammation and tissue fibrosis. In this narrative review, we provide a contemporary appraisal of TL1A-directed therapeutics in inflammatory bowel disease based on electronic searches through May 2026. Three anti-TL1A monoclonal antibodies (tulisokibart, afimkibart, and duvakitug) have advanced to phase 3 trials across multiple global programs, with phase 2 clinical remission rates of 26%-48% in ulcerative colitis (placebo-adjusted differences 15-26 percentage points) and endoscopic response rates of 26%-48% in Crohn's disease, alongside favorable safety profiles. Mucosal transcriptomic and serum proteomic analyses from phase 2 trials, including DDW 2026 readouts from ARTEMIS-UC and TUSCANY-2, provide the first human-tissue confirmation of class antifibrotic activity through the suppression of Th17, myeloid, and extracellular matrix pathways. TNFSF15 risk-variant companion diagnostics are advancing, although their incremental utility remains modest and will be definitively tested in phase 3. The pipeline has expanded to at least 19 development programs, including extended half-life antibodies (XmAb942, SPY002, and BCD-261), bispecifics combining TL1A with IL-23 or α4β7 (RO7837195, XmAb412, LQ080, and ALX001), a first-in-class oral anti-TL1A nanobody, and a first-in-class DR3 receptor antagonist (SL-325). We discuss therapeutic positioning and timing, the opportunity in acute severe UC, and the unusual standing of IBD as the lead indication for this mechanism class. Phase 3 results anticipated in 2026-2027 will be particularly informative for fibrostenotic phenotypes and biologic-refractory patients. - Source: PubMed
Publication date: 2026/08/27
Quraishi Mohammed NabilJairath VipulAl-Bawardy Badr - TNF-like cytokine 1A (TL1A) and its receptor DR3 form a key regulatory axis within mucosal immunity, integrating signals that promote Th1/Th17 responses, modulate innate lymphoid cells, and influence epithelial repair. Beyond inflammation, TL1A directly activates intestinal fibroblasts and contributes to extracellular matrix deposition, positioning the TL1A-DR3 pathway as a central driver of both chronic inflammation and fibrosis in inflammatory bowel disease (IBD). Genetic variants in TNFSF15, which encodes TL1A, further support a causal role, linking increased TL1A expression with susceptibility to Crohn's disease, ulcerative colitis, and fibrostenotic complications. Recent clinical trials of TL1A-neutralizing antibodies, including afimkibart, tulisokibart, and duvakitug, have demonstrated encouraging efficacy and safety in moderate-to-severe IBD, with emerging biomarker strategies suggesting potential for personalized treatment. Collectively, current evidence highlights TL1A blockade as a promising dual-pathway therapeutic approach targeting inflammation and fibrotic remodeling, with ongoing studies expected to define its long-term impact on disease modification. - Source: PubMed
Publication date: 2026/08/21
Tsuruta KozoYoshioka ShinichiroTakedatsu Hidetoshi - Tumor necrosis factor-like cytokine 1A (TL1A, TNFSF15) is a profibrotic and proinflammatory cytokine. Experimental evidence implicates TL1A-mediated interactions in interstitial lung disease (ILD); such interactions are disrupted by decoy receptor 3 (DcR3) binding to TL1A. We examined the potential clinical value of circulating TL1A and DcR3 levels in systemic sclerosis (SSc). - Source: PubMed
Publication date: 2026/08/20
Poulia VassilikiVlachogiannis Nikolaos IAvdi Aikaterini-ParaskeviBournia Vasiliki-KalliopiBamias GeorgeTektonidou Maria GSfikakis Petros PPanopoulos Stylianos - Ulcerative colitis (UC) and psoriasis (PS) are both chronic inflammatory disorders that frequently occur together in clinical settings. Nevertheless, the common genetic basis and biological mechanisms underlying this comorbidity remain insufficiently understood. - Source: PubMed
Publication date: 2026/08/11
Liu GuoWu NaLuo QinghuaHu Siyao - Osteoarthritis (OA) is characterized by cartilage degeneration, oxidative stress, and chondrocyte senescence. This study investigated whether TL1A promotes OA through ENO1-associated redox, senescence and PI3K-AKT signaling mechanisms. - Source: PubMed
Publication date: 2026/08/07
Gao XiangLi JuntanYin ChangyuLi KaiGao YuyangZhang ZihaoLi XuSun Xun